Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EO2040 |
Synonyms | |
Therapy Description |
EO2040 is a cancer peptide vaccine comprising microbiome-derived peptides homologous to tumor-associated antigens (TAA) and a CD4-positive T-cell epitope universal cancer peptide 2 (UCP2) emulsified with an immunoadjuvant, which potentially induces a cytotoxic T-cell response against tumor cells expressing the TAA (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EO2040 | EO-2040|EO 2040 | EO2040 is a cancer peptide vaccine comprising microbiome-derived peptides homologous to tumor-associated antigens (TAA) and a CD4-positive T-cell epitope universal cancer peptide 2 (UCP2) emulsified with an immunoadjuvant, which potentially induces a cytotoxic T-cell response against tumor cells expressing the TAA (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|